S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)María‐Victoria Mateos, Hila Magen, Kihyun Kım et al.|HemaSphere|2023Cited by 9
104 | A GLOBAL PHASE 1B STUDY OF JNJ‐90014496, A CD19/CD20 BI‐SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T‐CELL THERAPY, IN RELAPSED/REFRACTORY (R/R) LARGE B‐CELL LYMPHOMA (LBCL)Krina K. Patel, Matthew Ku, Joanna Rhodes et al.|Hematological Oncology|2025Cited by 0